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Summary 
Background 
One of the main activities of Health Technology Assessment (HTA) is the 
evaluation of new and emerging healthcare technologies. Disinvestment as a 
concept emerged from existing HTA activities and refers to the evaluation of 
technologies in their last stage of technology lifecycle. Many technologies 
currently in use have never been assessed; therefore disinvestment has 
started gaining attention as a policy approach for more efficient use of 
healthcare resources. 
Methods 
A systematic literature review was conducted in four databases to identify 
articles published in English. In addition to websites of HTA agencies, 
Google, Google Scholar and  grey literature were used to retrieve relevant in-
formation. 283 records were identified after deduplication overall. After 
screening and eligibility assessment 31 records were included. Selection cri-
teria were policy perspectives with a focus on disinvesting in obsolete or po-
tentially obsolete technologies. 
Research question 
This report investigates internationally used concepts of disinvestment, ex-
isting frameworks and guidelines for identification, assessment and dis-
semination of results of disinvestment recommendations. Four countries 
(England, Spain, Australia and Canada) are analyzed as specific examples of 
disinvestment related research and practices.  
Results 
An overview of disinvestment activities in England, Spain, Australia and 
Canada shows that disinvestment policies are at the developing/piloting 
phase. Only Spain has a formal methodological framework – the Guideline 
for Not Funding existing health technologies. The National Institute for 
Health and Clinical Excellence in England is recognized as already issuing 
mandatory disinvestment advice, however this might change after a new leg-
islation will be passed (Health and Social Care Bill 2011). Active discussion 
towards implementation of disinvestment policy was found in Canada and 
Australia, but actual projects are still in the piloting phase at regional level. 
Six generalized challenges are recognized from the experiences of these four 
countries. Main problems for a slow disinvestment process were identified as 
lack of resources and published evidence, lack of methodological framework, 
multiple interests and potential duplication of disinvestment efforts.  
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1 Introduction 
1.1 Background 
One of the main activities of Health Technology Assessment (HTA), often 
also referred to as “forth hurdle”, is the assessment of new and emerging 
health technologies prior to reimbursement decisions. In order to assess the 
potential impact of a new health technology on the health care system re-
garding the consequences for patients and for health professionals, many ef-
forts concentrated on the design and development of methods and standards 
for the assessment of safety, effectiveness and cost-effectiveness of those new 
and emerging health technologies.  
However, every health technology passes through different levels of devel-
opment throughout its lifetime (see figure 1-1) and eventually reaches the 
„obsolete technology” state. In addition, since the majority of health tech-
nologies already in use have never been assessed before, there is a growing 
interest in the detection and evaluation of obsolete technologies (1, 2) and 
only little evidence exists of the impact health systems are experiencing due 
to the usage of obsolete health technologies. 
However, “disinvesting” in already diffused technologies is not a mechanical 
cancellation of health technologies which prove to be ineffective, but a set of 
various factors have to be taken into account. Reviewing health services al-
ready in use could cause fears and dissatisfaction among patients and health 
professionals, as it might be seen as a reduction of the benefit packages. 
From HTA agencies’ perspectives, disinvestment can be seen as the possibil-
ity to broaden the scope of HTA activities by offering insight into effective-
ness, cost effectiveness and impact on healthcare budget of health technolo-
gies which are in use already. From the health care system’s view, identifica-
tion of obsolete technologies offers advantages in terms of increased effi-
ciency or  safety.  
An increase in research activities on disinvestment is noticeable since 2006. 
However, because almost no comprehensive systematic literature review on 
international disinvestment practices published until now, a research gap 
exists concerning methods for the implementation of disinvestment activi-
ties. This report thus aims to present a summary of experiences in setting up 
disinvestment agendas in four selected countries, to give an overview of ac-
companying challenges and to further stimulate discussion about the topic. 
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Experimental 
Conceptual stage, anticipated, or in ear-
liest stages of development 
Bench or laboratory testing using ani-
mals or other models 
Initial clinical (in humans) evaluation for 
a certain condition or indication 
Considered by providers to be standard 
approach to a condition or indication 
and diffused into general use 
Superseded by other technologies or 
demonstrated to be ineffective or harm-
ful
Investigational 
Established 
Obsolete, out-
moded, aban-
doned 
Future 
 
Figure 1-1. Stages of technological life cycle 
Source: Adapted from Goodman (3). 
1.2 Definitions  
1.2.1 Disinvestment 
Disinvestment is a relatively new concept and the majority of related litera-
ture dates from 2006. Many synonymous definitions such as “withdrawing 
from a service and redeploying resources”, “decommissioning”, “delisting”, 
“resource release”, “defunding” are used to refer to disinvestment and even 
the term “disinvestment” is not used homogenously. Even though no inter-
nationally accepted terminology was found, the most widely applied defini-
tion is the one provided by  Elshaug et al. (4): 
“disinvestment is the  process of (partially or completely) withdrawing 
health resources from any existing health care practices, procedures, tech-
nologies, or pharmaceuticals that are deemed to deliver little or no health 
gain for their cost and thus are not efficient health resource allocation”.  
new concept 
synonyms 
 
most used definition 
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Australian and Canadian researchers emphasized the distinction between 
rationing and disinvestment. Rationing is “withholding beneficial interven-
tions for cost reason”, while disinvestment focuses „on reducing ineffective 
or inappropriately applied practices, thus improving care and reducing 
waste without the need to withhold effective care through rationing ap-
proaches“ (5).  
 Furthermore differentiation is made between “explicit” and “implicit” dis-
investment , which other authors sometimes refer to as “active” and “pas-
sive” disinvestment (2, 6):  
„Explicit disinvestment refers to the process of taking resources from one 
service in order to use them for other purposes (i.e. reallocation of re-
sources). Implicit disinvestment is described as replacement and updating of 
practice and it occurs when a technology or intervention is superseded and 
therefore falls out of use“.  
1.2.2 Obsolete technologies 
The general meaning of obsolescence refers to the point in the health tech-
nology lifecycle when (7): 
“newer products or technologies supersede the old and when the costs of 
maintenance or repair outpace the benefits of the replacement technology“ 
 A more specific definition of obsolete health technologies is (8): 
“any health technology in use for one or more indications, whose clinical 
benefit, safety or cost-effectiveness has been significantly superseded by 
other available alternatives”. 
Differentiation is also made between “potentially obsolete” and “obsolete” 
technologies (8):  
“A potentially obsolete technology is one which is indicated as being possi-
bly obsolete after the process of detection, while an obsolete technology is 
one which is shown to be obsolete following the issue of a report based on a 
systematic review”. 
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2 Methods 
2.1 Objective 
The aim of this report was to provide a comprehensive overview of existing 
disinvestment approaches of selected countries in order to identify common 
challenges which might hamper introduction of disinvestment activities in 
other settings and to derive recommendations for the successful implemen-
tation of disinvestment strategies. 
The main intent of this report was to investigate existing practices of disin-
vestment activities to answer the following questions: 
 Is there an explicit framework for disinvestment activities? 
 What are the criteria for identification and prioritization of technolo-
gies for disinvestment? 
 How are disinvestment results disseminated among decision makers? 
 What are the challenges faced in the selected countries during the dis-
investment processes? 
The country specific information was analyzed to answer the first three 
questions whereas the last question aimed to generalize the overall informa-
tion in order to develop a non-country specific set of challenges and policy 
suggestions. 
2.2 Literature search 
A systematic literature search was conducted in April 2011 to identify the 
relevant literature (the detailed search strategy can be found in the appendix 
7.1). Following databases were searched: 
 Ovid  Medline 
 EMBASE 
 Centre for Review and Dissemination databases 
 Cochrane Library 
The searches were restricted to articles published in English from 1949 – 
April 2011. 390 records were identified. 
The bibliographies of identified key articles were hand searched for any oth-
er relevant articles. As the majority of the literature came from only a few 
countries (England, Spain, Australia and Canada), with disinvestment sys-
tems already in place, the analysis of possible approaches were restricted to 
information available on the websites of HTA institutions of those countries:   
review of existing 
approaches to 
disinvestment 
research questions: 
framework 
identification & prioritization 
of technologies 
result dissemination 
challenges 
systematic literature 
search 
 
web searches 
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 National Institute for Health and Clinical Excellence – NICE (Eng-
land) 
 Basque Office for Health Technology Assessment – OSTEBA (Spain) 
 Galician Agency for Health Technology Assessment – Avalia-T 
(Spain) 
 Canadian Agency for Drugs and Technologies in Health – CADTH 
(Canada) 
 Medical Services Advisory Committee – MSAC (Australia) 
 Pharmaceutical Benefits Advisory Committee – PBAC (Australia) 
 Adelaide Health Technology Assessment – AHTA (Australia) 
In addition, web searches, using Google and Google Scholar search engines 
were conducted to identify grey literature such as conference abstracts, post-
ers, slide sets and press releases. Literature identification from sources other 
than databases led to additional 45 records.  
2.2.1 Literature selection 
Selection criteria were articles on methodology focusing on disinvesting in 
obsolete or potentially obsolete technologies in general or providing an over-
view on one of the four selected countries. 
The systematic search identified 283 records after deduplication. In total, 31 
papers were included. A considerable part of the information in this report 
came from the grey literature – slide sets, conference abstracts, posters. In-
formation from national HTA agencies websites were used for specific 
disinvestment related information and for background information on 
country specific HTA activities (see Annex 7.2).  
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(n = 51 ) 
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cluded (not selected 
countries specific) 
(n = 25 ) 
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qualitative synthesis 
(n = 31 ) 
Information from other countries than England, Spain, Australia and Can-
ada were identified in the form of slides or pilot project description, but 
not included in further analysis due to fragmented information available.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.1-1: Flow diagram of studies selection. 
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2.3 Concept of disinvestment used in this 
report 
A common terminology was not found in the papers analyzed and the most 
often used terms “disinvestment” and “obsolete technology” are not used 
distinctively. In this report, the term “disinvestment” is used focusing on 
“active disinvestment”. The term “obsolete technology” is used in all en-
compassing comprehensive meaning (including the term “potentially obso-
lete”), referring to any health technology, drug or intervention at their last 
stage of technology lifecycle.  
2.4 Limitations 
An inclusion of literature published in English only might be a limitation. 
However as no key articles in languages other than English were identified 
and due to the availability of HTA websites in English, it is unlikely that 
any key information on the research topic has been missed. 
 
 
terminology not used 
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focus on “active 
disinvestment” 
in English 
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3 International experiences of disinvestment 
This chapter describes the disinvestment experiences of HTA institutions 
from England, Canada, Spain and Australia (NICE, CADTH, MSAC, 
PBAC, AHTA, OSTEBA and Avalia-T). General information of the HTA 
agencies can be found in the Annex 7.2.  
Initiatives for disinvestment were also identified in Scotland, Italy, France 
and Denmark, but due to minimal and fragmented information provided 
and no broad scale disinvestment projects identified, these initiatives were 
excluded from a comprehensive analysis.  
The methods of the selected institutions were analyzed focusing on the fol-
lowing aspects: 
 Processes for the identification of obsolete technologies  
 Assessment of technologies at the end of their lifecycle  
 Strategies for the dissemination and uptake of the disinvestment deci-
sions. 
3.1 Overview of disinvestment activities in 
selected countries 
3.1.1 England 
The disinvestment agenda first emerged in 2005, as part of the healthcare 
system reform. In 2006, the Department of Health/DoH gave NICE an offi-
cial mandate to develop a framework for the identification and assessment of 
ineffective interventions (5). Critique followed two years later, when the 
House of Commons Health Committee noticed that no evaluations of older 
therapies had taken place, and that disinvestment activities had not been en-
forced. The Committee suggested to conduct more Multiple Technology As-
sessments (MTAs are reports that examine whole disease areas or classes of 
drugs (9)) in order “to reveal existing treatments which provide poor value 
for money (10)”. The Research & Development (R&D) team of NICE re-
sponded in 2009 claiming to have produced “at least four key NICE ‘disin-
vestment’ recommendations on average each month (11)”. 
In addition, several  Primary Care Trusts (PCTs (12) - public authorities in 
England responsible for planning, securing, funding and coordinating all of 
the NHS services in a defined geographical area) have initiated local disin-
vestment activities (13).  
On a national level, however, and despite the official mandate, NICE has not 
published a comprehensive framework for disinvestment till now. 
3.1.2 Spain 
In 2006, a national law opened up the possibility to exclude  any health tech-
nology which “lacks efficiency, effectiveness, efficacy or has an unfavourable 
risk-benefit ratio” (14). This law supported a regional  legislation of the 
experiences in CA, 
AU, ES, England 
initiatives in other 
countries 
focus on: 
 
identification 
assessment 
dissemination 
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 local initiatives of 
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Disinvestment 
18 LBI-HTA | 2011 
Basque country issued in 2004 which stated that managers of Basque Health 
Service (BHS) “should inform the BHS director about those technologies 
that are no longer being used” (14). However the Basque law did not provide 
definitions or more specific criteria of the technologies which ought to be 
reported. 
Starting in 2007, two regional HTA agencies (OSTEBA and Avalia-T) initi-
ated a project “The identification, prioritisation and evaluation of poten-
tially obsolete health technologies” (2, 15). Avalia-T, the Galician HTA 
agency, published an initial version of methodological guidelines for identi-
fication, prioritization and assessment of obsolete health technologies, and 
developed PriTec, a publicly available web-based tool for the prioritization 
of potentially obsolete health technologies. In 2010, the report on the devel-
opment of GuNFT, the “Guideline for Not Funding existing health Tech-
nologies in health care systems”, was published. It is the first and only com-
prehensive guideline for technological disinvestment in healthcare till now. 
Disinvestment activities in Spain related to GuNFT include (16): 
 a program for the introduction of GuNFT in the BHS hospitals 
 an agreement between HTA agencies to implement a disinvestment 
process in the Spanish Health System  
 a pilot project to test GuNFT in Spain and UK hospitals (North West 
region, Manchester) 
Mid-term review and final internal evaluation is planned to be conducted in 
Basque and Galician regions, however no evidence of the evaluations taking 
place or results have been found. 
3.1.3 Australia  
In 2009, the Department of Health and Ageing conducted an extensive re-
view of any ongoing HTA activities in Australia and made a formal proposal 
for a “Review process with capacity to recommend disinvestment (1)”. In the 
same year, funds were allocated by the government to Medicare (national 
health program which covers only services listed on the Medicare Benefits 
Schedule (MBS)) for the development of the “Quality Framework”, an evi-
dence based framework to identify  health technologies already listed in 
MBS for further evaluation (17).  
Despite the availability of various publications, conferences and seminars, 
no comprehensive framework has been published yet.  
3.1.4  Canada 
First “delisting” activities were initiated at a regional level in Canada al-
ready in the 1990s, but were, due to lobbying activities of medical groups, 
unsuccessful (5). In 2009, an approach was proposed for disinvestment of 
obsolete technologies in a discussion working paper (7) by the Canadian 
Agency for Drugs and Technology in Health (CADTH): the “Oversight 
Committee” should be established as a coordinating oversight body or as a 
part of existing HTA entity for managing standard approaches to disinvest-
ment at national level.  
Osteba and Avalia-T: 
project 
GuNFT 
PriTec tool 
introduce GuNFT in 
hospitals  
pilot project ES-
England 
results not available 
yet 
DoHA review 
MBS quality 
framework 
discussions 
“Oversight 
Committee” proposed 
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Another project at the provincial level addressed the budget deficit of the 
Vancouver Coastal Health Authority. This project was undertaken to inves-
tigate options for resource re-allocation. As a result, recommendations for 
disinvesting in 44 health technologies were made (1). No national level dis-
investment plan exists.  
3.2 Identification and prioritization of 
obsolete technologies 
3.2.1 England 
No formal criteria set according to which NICE selects technologies for dis-
investment are available. Recommendations fromCochrane reviews of tech-
nologies for which there is little or no evidence of benefit are used since 2006 
for identifying relevant topics for disinvestment (18). However, no specifica-
tions of this process were found. 
Supported by the results of the Audit Commission and as part of NICE’s ini-
tiative on disinvestment, characteristics for identifying and prioritizing the 
list of appraisal topics for disinvestment are suggested  (13, 18, 19): 
 a significant overall budget impact 
 existence of currently underused effective alternative technologies 
with demonstrated cost-effectiveness 
 impact on patient safety 
 possible impact on vulnerable groups 
 benefit and risk balance is close 
Prime candidates for disinvestment considered by some authors are thus 
cosmetic procedures, “me too” drugs (duplicates within same drug class with 
only minor differences) and “evergreens” (drugs with soon-to-elapse pat-
ents), as well as branded products with generic alternatives (18).  
3.2.2 Spain 
Specialists’ networks and high quality systematic reviews are suggested to be 
the most efficient way to detect potentially obsolete technologies among 
provided healthcare services. Avalia-T suggests four specific approaches and 
sources for the identification of obsolete technologies in Spain (8): 
 Direct consultation of medical literature (e.g. Medline database) 
 Consultation of new and emerging technology databases  
  Consultation of systematic reviews published in the literature or by 
HTA agencies 
 Consultation with institutions responsible for updating portfolios of 
the National Health System, hospitals or regional services. 
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The PriTec tool was developed to help prioritizing health technologies for 
disinvestment. It allows the comparison of up to 50 technologies and gener-
ates a prioritisation report to be used for assessment purposes (2). The pri-
oritization criteria according to PriTec are grouped into three categories (20, 
21): 
 Population/end-users: frequency of disease, burden of disease, fre-
quency of the use of the obsolete technology, patients’ preferences  
 Risk/benefit: efficacy, effectiveness, reliability, adverse effects 
 Costs, organisation and other implications. 
No published data are available to assess the effectiveness or impact of the 
PriTec tool (2). 
3.2.3 Australia  
The Medical Services Advisory Committee (MSAC) and Pharmaceuticals  
Benefit Advisory Committee (PBAC) have the capacity to disinvest in health 
technologies in Australia by recommending withdrawal of reimbursement, 
but  explicit criteria for identification and prioritisation of obsolete tech-
nologies was found just in PBAC, which is responsible for the centralized 
review of new drugs and has explicit criteria for removing drugs from the 
PBS  (17): 
 availability of more/equally effective but less toxic drugs  
 evidence of unsatisfactory effectiveness emerges 
 toxicity/abuse potential of the drug outweighs therapeutic value 
 drugs is misused or no longer available 
 drug is no longer deemed cost effective in comparison to other thera-
pies. 
Elshaug et al., leading researchers on disinvestment in Australia, propose a 
comprehensive set of criteria to be used for identification and prioritisation 
of disinvestment candidates. These suggestions are adapted from criteria 
and sources which are used by Australia and Canada for HTA and horizon 
scanning processes (22): 
Criteria: 
 New evidence on safety, effectiveness and/or cost effectiveness.  
 Geographic variations in care (demographic adjustments and the lo-
cation of centres of excellence can suggest differences in clinical opin-
ion about the value of the interventions) 
 Provider variations in care, where the choice of intervention varies for 
the same class of disease or condition 
 Temporal variations in volume between time points (e.g. 2, 3 or 5 
years), of a substantial percentage (e.g. 30%, 50% or 80%) 
 Technology development: when an intervention has evolved substan-
tially from the initial intervention that was originally assessed or 
funded, then the initial intervention should be reviewed 
 Public interest or controversy  
 Leakage: technology use outside the evidence-based indications. 
PriTec: comparison of 
technologies 
generates a report 
criteria: 
population/end users 
risk/benefit 
costs/other 
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 Legacy items: long-established technologies that have never had their 
cost effectiveness assessed  
 Usage conflicts with clinical practice guidelines, clinical college posi-
tion statements or Cochrane Review recommendations.  
 
Sources and processes: 
 Consultation with all stakeholders in healthcare provision 
 Nomination process, where individuals, associations and colleges 
could nominate interventions and justify their choice  
 Assessing new intervention and displacing old: when a new interven-
tion is presented for regulatory assessment, and is considered a poten-
tial replacement for an established comparator for that indication, 
then that comparator for that patient indication should automatically 
be considered and assessed for disinvestment. 
 
After identification of candidates for disinvestment Elshaug et al. suggests to 
prioritize the candidates for a detailed review using following criteria (22): 
 Costs of service 
 Potential impact (likely health impact, cost effects and access by pa-
tient subgroups) 
 Cost effective alternatives 
 Burden of disease 
 Availability of sufficient evidence 
 Scope for time limited funding (with “pay for evidence” or “only in 
research” provisions) 
 Futility (interventions that patient have poor adherence to due to 
pain or side effects; treatments with high relapse rates) 
Even though other countries refer to these suggestions, there is no evidence 
that these comprehensive criteria were formally recognized elsewhere. 
3.2.4 Canada 
CADTH does not have a formal process of identifying obsolete health tech-
nologies. The “Oversight Committee” model proposed by Joshi et al. (7). 
would be responsible for the development and implementation of identifica-
tion and priority-setting processes for technologies considered to be poten-
tially obsolete. Proposed triggers to initiate inquiring about a potentially ob-
solete technology are (7): 
 Obsolescence forecasting of health technologies (horizon scanning, fo-
cusing on identifying candidates for disinvestment via the alternatives 
provided) 
 Reassessment of related or adjacent technologies activated by assess-
ment or adoption of new health technologies 
 Provincial or regional requests/decisions based on experience 
 New evidence on safety, efficacy, cost-effectiveness 
legacy items 
conflict with 
guidelines 
consulting 
stakeholders 
nomination 
assess new, displace 
old 
prioritization criteria 
cost 
potential impact 
available alternatives 
burden of disease 
sufficient evidence 
limited funding 
futility 
CADTH: no formal 
process 
triggers for 
assessment 
obsolescence 
forecasting 
related technologies 
provincial/regional 
requests 
new evidence 
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 Timed mechanism (an agreement that in the e.g. 5 years after ap-
proval/introduction of a new health technology, a review would be 
conducted) 
No evidence was found whether the “Oversight Committee” model was ac-
tually implemented.  
3.3  Assessment of obsolete technologies 
3.3.1 England  
NICE’s methods for assessing candidates for disinvestment are the same as 
for investment. In 2006, it was stated that the methodology for assessing ob-
solete technologies will be based upon the Single Technology Appraisal 
(STA) process (23) which is  
“Specifically designed to appraise a single product, device or other technol-
ogy, with a single indication. It enables NICE to produce guidance soon af-
ter the technology is introduced.”  
In 2009, the recommendation was made by the House of Commons Health 
Committee to NICE to conduct more MTAs instead of STAs for the detec-
tion of disinvestment candidates (10). However, it remains unknown 
whether these recommended changes were actually implemented and no de-
tails on disinvestment-specific methods used by NICE were found. Standard 
HTA methods used for STAs and MTAs are used for investment, as well as 
disinvestment assessments. 
3.3.2 Spain   
No specific methodology, besides standard HTA methods, for assessing ob-
solete technologies were found in Spain. GuNFT stressed the importance of 
conducting systematic reviews. Additionally, Avalia-T proposed the stan-
dard structure of obsolete health technology reports to be used and empha-
sized the importance of systematic reviews as well.  According to a suggested 
structure for obsolete HTA reports, the following parts should be covered 
(8): 
 Information on potentially obsolete technology (name, type, year of 
adoption, indications) 
 Contextualization of technology (incidence/prevalence of disease, 
numbers of patients estimated, diffusion and implementation of tech-
nology, infrastructure necessary) 
 Results of efficacy, effectiveness, safety, cost and organization  
 Level of scientific evidence 
 Conclusions and recommendations 
Reports on disinvestment with standardised structure would facilitate trans-
ferability of disinvestment research. 
timed mechanism 
STA – methodology 
for disinvestment 
MTAs recommended 
systematic reviews 
essential 
standard structure for 
disinvestment report 
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3.3.3 Australia  
No disinvestment specific methodology in use was found in Australia. The  
number of reviews of existing technologies is limited – as of January 2010, 
only 3% of items in Medicare Benefits Schedule were reviewed via standard 
HTA procedures focusing on safety, effectiveness and cost-effectiveness (17, 
24). 
3.3.4 Canada 
A methodological framework for disinvestment assessments published either 
by CADTH or regional agencies was not found. Program Budgeting and 
Marginal Analysis (PBMA) was identified as a commonly used method for 
multi-criteria decision analysis for disinvestment like activities. PBMA is a 
tool for priority setting  while applying cost effectiveness principles through 
the analysis of the relationship between marginal costs and marginal bene-
fits (25). The Vancouver Coastal Health Authority also used PBMA in their 
resource allocation analysis.  
The “Oversight Committee” model suggested assessments for disinvestment 
to be performed in the same ways as standard HTA, with additional empha-
sis on a contextual analysis, determining effects of a new technology on a 
treatment regimen and stakeholders. Best practice protocols, based on clinical 
consensus and expert opinion should be the potential result of this reas-
sessment process. The classification of reassessed technologies would lead to 
a database of technologies labelled as “appropriately used” or  “misused”, 
“overused” and “obsolete” (7).  
3.4 Dissemination of disinvestment 
recommendations 
3.4.1 England 
NICE has recognized the need to integrate disinvestment recommendations 
into guidance development. Products of NICE to specifically disseminate 
disinvestment recommendations include (23, 26, 27):  
 Recommendation reminders are published monthly and highlight se-
lective “do not do” recommendations from NICE’s clinical guidelines. 
They aim to remind clinicians and NHS managers of already existing 
advice from NICE which can result in possible savings. There were 45 
recommendation reminders published between 2000 and 2006. 
 Commissioners’ guides are topic specific, web based resources, focus-
ing on areas where investment and disinvestment is required. It in-
cludes practical advice for NHS commissioners on methods to com-
mission routine services and provides data for local decision making. 
37 Commissioners’ guides have been published since 2006. 
  “Do Not Do” database is a tool supporting disinvestment activities 
and contains clinical practices that should be refrained from or 
should not be used routinely. These practices were constantly identi-
only 3% in MBS 
reviewed 
PBMA 
contextual analysis 
integrate disinvestment 
into guidance 
development 
recommendation 
reminders 
commissioners´ guides 
“Do Not Do” database 
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fied during the process of standard guidance development.  The data-
base comprises recommendations from NICE’s cancer service guid-
ance, clinical guidelines, interventional procedures and technology 
appraisal guidelines. 650 “Do Not Do” recommendations were pub-
lished between 2007 and 2011.  
3.4.2 Spain 
Even though no existing strategies for dissemination of disinvestment re-
sults were found at the national level, informing patients and health profes-
sionals were identified as key factors to facilitate the acceptance of individ-
ual disinvestment recommendations. Therefore GuNFT suggests that an 
implementation strategy should be developed as the last stage of the disin-
vestment process where health authorities, local hospitals, patients and 
health professionals are notified on decision to disinvest in specific tech-
nologies.  Monitoring and evaluation of the implementation of GuNFT are 
expected to be conducted in Basque and Galician regions, but no results of 
evaluation are available at the moment. 
3.4.3 Australia  
No specific strategy for dissemination of disinvestment results and commu-
nicating them to the public, health professionals and other decision makers 
in Australia was detected. Concerning delisting of drugs, both PBAC and 
MSAC have the right to recommend withdrawal of reimbursement. Cases 
have been noted of companies themselves withdrawing superseded drugs 
from the market (24). 
3.4.4 Canada 
No specific method for the dissemination of disinvestment results was found 
in any HTA agency/group in Canada. The future dissemination activities in 
Canada could use well established pathways of standard HTA results dis-
semination. For communication of HTA results to stakeholders and the pub-
lic, CADTH identifies partners and develops dissemination strategies al-
ready during the report writing stage (28). Standard methods of research re-
sults distribution was found in CADTH and regional HTA agencies: pub-
lished reports, articles in scientific journals, conference presentations, web-
based tools, workshops, press releases, etc. The Canadian Institute of Health 
Economics (IHE) was identified  additionally using specific dissemination 
tools as “ambassador programme for knowledge transfer” and “Consensus 
Development Conferences” (29, 30).  
no  specific strategy 
monitoring of GuNFT 
no results yet 
companies withdraw  
technologies 
themselves 
no strategy 
dissemination 
strategy  in all HTA 
reports 
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3.5 Overview 
Table3.5-1: Overview of disinvestment processes in selected countries 
 England and Wales Spain Australia Canada 
HTA agencies NICE 
Osteba 
Avalia-T 
MSAC 
PBAC 
CADTH 
Competence 
level national regional national national 
Published 
disinvestment 
framework 
No GuNFT guideline No No 
Identification & 
prioritization Criteria proposed PriTec tool Criteria proposed Criteria proposed 
Criteria 
 Budget impact 
Existing alternatives 
Improved patient safety
Not for vulnerable 
populations 
Small benefit 
Close risk/benefit ratio 
 
Efficacy 
Effectiveness 
Reliability 
Adverse effects 
Costs 
Frequency of 
disease 
Burden of disease 
Patients’ 
preferences 
Frequency of the 
usage 
Evidence on safety 
Effectiveness/cost 
effectiveness 
Geographic 
/provider/volume 
variations 
Technology 
development 
Public opinion 
Available 
alternatives 
Legacy items 
Conflict with 
guidelines 
Costs 
Burden of disease 
Futility 
Availability of 
evidence 
PBAC criteria for 
drug removal: 
Toxicity 
Unsatisfactory 
effectiveness 
Misuse 
Cost effectiveness 
Forecasted 
obsolescence 
Assessment of 
related technologies
Provincial/regional 
requests 
Evidence on safety
Efficacy 
Cost effectiveness
 
Assessment 
methodology Standard HTA methods
Standard HTA 
methods 
Standard HTA 
methods 
Standard HTA 
methods 
PBMA 
Dissemination 
of results 
Recommendation 
reminders 
Commissioners’ guides 
“Do Not Do” database 
n.a. n.a. n.a. 
Disinvested 
technologies  n.a. n.a. n.a. n.a. 
Source: compiled by author. 
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4 Conclusion: Challenges 
Disinvestment is rather a new concept in HTA and its introduction can pose 
serious challenges. Even though these challenges are influenced by contex-
tual circumstances and might thus vary strongly between countries, several 
hindrances occurred repeatedly in all four countries. It can therefore be ex-
pected that any other country, starting disinvestment policies, would face 
similar challenges. Possible strategies to overcome those problems should 
thus be identified early, ideally during the preparation stage of any disin-
vestment activity. 
4.1 Terminology 
In absence of any formal definition of “disinvestment”, there is a wide vari-
ability in terms used to describe disinvestment activities (e.g. low clinical 
value, limited clinical value, inefficient, ineffective and relatively ineffec-
tive, obsolete and potentially obsolete). It leads to impediments in literature 
and information searches as well. Furthermore no indications were found 
that explicit criteria exist at the national level in any of the four countries, 
which would determine obsolete or potentially obsolete technologies.  The 
perception of the obsolescence of a technology depends on the circumstances 
of each country, and differentiation is expected between definitions, thus 
implying complications in the transferability of disinvestment recommenda-
tions. 
4.2  Resources 
Lack of dedicated resources to build and support disinvestment mechanisms 
is one of the most common challenges identified in all four countries ana-
lyzed. All steps of disinvestment activities – identification and prioritisation 
of obsolete technologies, actual assessment and dissemination of results – 
create additional costs stressing the budgets of HTA agencies (5).  Moreover, 
professionals with the sufficient expertise and the necessary skills to initiate 
disinvestment projects, and to identify and assess obsolete technologies are 
scarce. 
4.3 Framework 
There is a lack of reliable valid methods to identify, prioritise and assess ob-
solete technologies and to disseminate the results of disinvestment recom-
mendations. Discussions about disinvestment activities had been taking 
place in all four countries, but only Spain has published a specific guideline 
for disinvestment in healthcare.  
generalized 
challenges 
variability in 
definitions 
additional costs 
lack of resources 
lack of expertise 
formal guideline only 
in ES 
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The issue of identifying potential candidates for disinvestment was repeat-
edly addressed, bearing the danger of an intransparent and random selection 
of treatments, interventions and services. Even though criteria for identifica-
tion and prioritisation of health technologies for disinvestment are provided 
in all countries, but none of them are, besides GuNFT, incorporated in for-
mal guidelines.  
Standard HTA methods for disinvestment activities were found in all or-
ganizations analyzed. However, there are no large scale disinvestment pro-
jects conducted yet, therefore the evaluation of the methodology is impossi-
ble at this stage – future evidence will define whether standard HTA meth-
odology for disinvestment is sufficient, needs adaption or new methods 
should be formulated. 
Dissemination of disinvestment recommendations is regarded crucial in all 
countries investigated, however no specific strategies for disinvestment re-
sults’ enforcement were found. Moreover, the lack of data available about 
disinvested technologies and monetary gains from these disinvestments 
makes it impossible to compare the effectiveness of countries’ approaches to 
national disinvestment agendas’ implementation. 
Hence, it is not clear whether any of the approaches of Australia, Spain, 
Canada and England can be regarded as best practice model for other coun-
tries. 
4.4  Availability of evidence  
As the majority of technologies used in clinical practice in all of the four 
countries has never been assessed before, comprehensive evidence on possi-
ble harm and cost effectiveness of health technologies are often lacking  (31).  
4.5 Duplication of efforts 
Duplication of efforts in disinvestment may occur, especially when no com-
prehensive national framework is in place. In England, for example, some 
PCTs have started initiating their own evaluations of clinical effectiveness, 
disinvesting at the local level, because the national strategy for disinvest-
ment proceeded slowly (13).  The challenge of the duplication efforts and re-
sults can be aggravated in countries with decentralized structures (e.g. de-
centralized healthcare service delivery and/or decentralized HTA) and fail 
to achieve the goal of effective use of scarce health care resources. 
4.6 Local priorities and multiple interests  
Local priorities can become a challenge while implementing national disin-
vestment plans. Some authors claim that local conditions can determine the 
rationale for keeping a service in one area, while eliminating it in another 
[10], potentially causing “postcode” rationing, which, in the end, leads to 
differences in coverage and treatment access for patients. 
difficult to identify 
candidates for 
disinvestment 
methodology used – 
not evaluated 
lack of dissemination 
strategies 
lack of evidence on 
harm/cost 
effectiveness 
duplicated efforts 
duplicated local 
initiatives 
waste of resources 
local conditions 
postcode rationing 
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Influences of clinicians and consumers, patients’ preferences, supplier-
induced demand and political interests were also identified as possible chal-
lenges. Inclusion of health professionals in disinvestment decision making 
was proposed as one strategy to overcome these diverging interests and as a 
means for the successful implementation of disinvestment projects. How-
ever, previous studies show, that health professionals are reluctant to ration 
health care services (32) and disinvestment might be perceived as a ration-
ing instrument, which will restrict clinical autonomy and reduce patient 
choice  (4). 
Furthermore, other groups, such as the public and the media, might have 
difficulties accepting the need for disinvestment in healthcare, because the 
term “disinvestment”  may suggest reduced investment and denial of access 
to some services. Therefore, disinvestment might mainly be associated with 
cost reduction strategies, rather than with a coordinated policy to maximise 
the returns of investment in health care (33). Also, disinvestment decisions 
can be controversial and raise ethical questions if vulnerable groups such as 
children, disabled or retirees are affected. Disinvestment in those services 
could raise public critique and could slow down disinvestment implementa-
tion processes. Despite acknowledging this fact, none of the four countries 
has specific strategies for disinvestment regarding technologies which pro-
vide benefits for vulnerable groups.   
 
different interests 
reluctance to ration 
care 
might be associated 
with reduced care 
effects on vulnerable 
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5 Recommendations 
The process of introducing disinvestment activities in healthcare systems is 
complex and subject to regional as well as national circumstances.  Despite 
these differences similarities were found among institutions investigated. 
There exists resemblance in criteria proposed for identification and prioriti-
sation of candidates for disinvestment – new evidence on effectiveness, effi-
ciency, cost effectiveness, safety, and available alternatives. Furthermore, 
the analysis shows the homogeneity in the methodology used/proposed to be 
used while assessing potentially obsolete technologies – all institutions rely 
on standard HTA methods. 
No comprehensive national disinvestment framework at national level was 
found.  Moreover, available evidence of implementation of disinvestment 
recommendations is extremely fragmented or not to be found at all in the 
countries analyzed. 
Nonetheless, several challenges were identified in all four countries as, for 
example, the methodology of identification, prioritization and assessment of 
obsolete technologies needs further refinement and strategic plans for disin-
vestment agendas need to be developed for the incorporation into ongoing 
HTA activities. The very last challenge remaining is the assessment of the 
actual impact of disinvesting as realistic estimations of possible savings due 
to disinvestment seem to be speculative, because a formal method for quan-
tifying savings and benefits from disinvestment has not been proposed and 
no actual evaluation has been taken place yet. 
Based on the challenges identified, some recommendations can be made 
which facilitate the implementation of disinvestment activities.  
 Firstly, transparent disinvestment framework should be developed 
through a process involving health professionals, national and re-
gional health authorities, patient groups, insurances and strong com-
mitment is required from all stakeholders.  
 Also, decision-makers as well as stakeholders need to be aware, that 
disinvestment requires a long term strategy, since results are not easy 
to be quantify from the very early on-set.  
 Testing proposed disinvestment strategies in pilot projects before in-
troducing comprehensive national disinvestment policy would also be 
beneficial, as early identification of barriers would provide informa-
tion for better preparation of large scale future disinvestment pro-
jects. Some of the identified disinvestment activities can be seen as pi-
lot projects (e.g. GuNFT implementation in Basque region, PCTs lo-
cal disinvestment activities in England, Vancouver Health Authority 
project in Canada) and detailed results of their experiences will be 
crucial for expanding disinvestment activities at national level. 
 Disinvestment requires increase in resources and capacities used, 
therefore additional funding should be assigned for institutions con-
ducting disinvestment activities in parallel to standard HTA, or 
streamed towards establishment of new institutions specifically des-
ignated to research in disinvestment and obsolete technologies.  
 In addition, international collaboration in disinvestment could bene-
fit the participants greatly. Exchange of research information as well 
as access to different databases of interventions which are deemed to 
complex process 
similarities in criteria 
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no comprehensive 
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common challenges 
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be ineffective would reduce the workload for all agencies, requiring 
only the adaption to local settings. 
 
Despite the general factors facilitating the implementation of disinvestment 
strategies, in the absence of evaluations of any of these disinvestment initia-
tives, it is difficult to assess the effectiveness of the different approaches and 
to determine a best practice model yet.  
 
best practice cannot 
be determined 
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7 Appendices 
7.1 Search strategies 
Search strategy for Medline 
Date: 15 April 2011 
Database: Ovid MEDLINE 
1. disinvestment*.mp.  
2. Obsolete technology.mp.  
3. Obsolete technologies.mp.  
4. (Obsolescence adj3 (technolog* or intervention*)).mp. 
[mp=protocol supplementary concept, rare disease supplementary 
concept, title, original title, abstract, name of substance word, sub-
ject heading word, unique identifier]  
5. ineffective intervention*.mp.  
6. ineffective technology.mp.  
7. ineffective technologies.mp.  
8. 1 or 2 or 3 or 4 or 5 or 6 or 7  
 
Search strategy for Embase 
Date: 18 April 2011 
Database:  EMBASE 
1. disinvest* 
2. 'obsolete technology' 
3. 'obsolete technologies' 
4. obsolescence NEAR/2 (technolog* OR intervention*) 
5. 'ineffective intervention' 
6. 'ineffective interventions' 
7. 'ineffective technology' 
8. 'ineffective technologies' 
9. #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 
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Search strategy for CRD 
Date: 19 April 2011 
Database: Centre for Reviews and Dissemination database 
 
1. (disinvestment*) OR (Obsolete NEAR technolog*) OR (Obsoles-
cence) OR (ineffective NEAR intervention*) OR (ineffective NEAR 
technolog*) 
 
Search strategy for Cochrane Collaboration 
Date: 18 April 2011 
Database: Cochrane Library 
1. disinvestment* 
2. Obsolete technolog* 
3. Obsolescence 
4. "ineffective intervention" 
5. "ineffective interventions" 
6. ineffective NEAR technolog* 
7. (#1 OR #2 OR #3 OR #4 OR #5 OR #6) 
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7.2 Overview of HTA in selected countries 
Table 8.2-1. Overview of HTA and disinvestment in Canada, Australia, Spain 
and England. 
 England  Spain Australia Canada 
Healthcare decision 
making Centralized Decentralized Centralized Decentralized 
HTA institution(s) NICE 
OSTEBA 
Avalia-T 
MSAC 
PBAC 
AHTA 
CADTH 
Characteristics of 
HTA institution(s) 
Assessing just 
technologies 
which have 
“major health 
implications, 
budget impact or 
contraversary 
over 
effectiveness”. 
Recommendation
s are required to 
be implemented 
by PCTs within 3 
months. 
Appraisal via 
MTA or STA. 
Regional HTA 
agencies 
responsible for 
producing 
information on 
the efficacy, 
effectiveness, 
safety and 
efficiency of new 
health 
technologies. 
Recommendation
s of regional 
agencies are not 
national standard 
MSAC: provides 
advice to DoHA 
that relate to the 
health 
technologies 
listed on MBS. 
PBAC makes 
advice to DoHA 
on which drugs 
that should be 
made available 
through the PBS. 
Regional HTA 
authorities guide 
regional HTA 
processes. 
CADTH is 
responsible for 
supplying 
assessments to 
federal, 
provincial or 
territorial 
healthcare 
policymakers. 
 
Recommendation 
status Binding Non binding Non binding Non binding 
